Lower mean corpuscular hemoglobin levels as a predictive factor of future exacerbations in patients with chronic obstructive pulmonary disease
- PMID: 39764900
- DOI: 10.1016/j.resinv.2024.12.008
Lower mean corpuscular hemoglobin levels as a predictive factor of future exacerbations in patients with chronic obstructive pulmonary disease
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a pulmonary and systemic inflammatory disease, and the management of systemic comorbidities is important. We previously reported that a lower mean corpuscular hemoglobin concentration (MCHC) at admission was an independent prognostic factor for death in patients with COPD exacerbation. This study aimed to determine the association between MCHC levels and prognosis in patients with stable COPD.
Methods: Overall, 200 stable patients with COPD (mean age; 71.0 ± 8.4 years, male; 93.5%) from January 2014 to March 2020 who were followed up for 4.6 ± 0.7 years were included. During the observation period, 70 patients experienced COPD exacerbations.
Results: Significantly lower body mass index and more severe pulmonary function were observed in patients with COPD exacerbations than those without. The serum levels of aspartate aminotransferase and alanine aminotransferase, lymphocyte counts, and hemoglobin and MCHC levels in peripheral blood in patients with COPD exacerbation were significantly lower than those in patients without exacerbations. Multiple logistic regression analysis revealed that a lower MCHC level was an independent predictive factor of COPD exacerbations during the observation period, even after adjusting age, BMI, ACO merger, COPD grade, and emphysema severity, which were significantly different in univariate logistic regression analysis.
Conclusion: MCHC levels are a significant biomarker for assessing the future risk of exacerbations in patients with COPD, indicating usefulness of measurement of MCHC levels in the management of patients with COPD.
Keywords: Chronic obstructive pulmonary disease; Exacerbation; Mean corpuscular hemoglobin concentration; Predictive factor.
Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest Sumito Inoue received lecture fees from AstraZeneca, KYORIN Pharmaceutical, and Novartis Pharma. Masafumi Watanabe received lecture fee from Boehringer Ingelheim JP. The other authors have no conflict of interest.
Similar articles
-
Association between low mean corpuscular hemoglobin and prognosis in patients with exacerbation of chronic obstructive pulmonary disease.Respir Investig. 2021 Jul;59(4):498-504. doi: 10.1016/j.resinv.2021.01.006. Epub 2021 Feb 26. Respir Investig. 2021. PMID: 33642232
-
Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Inflammation. 2015 Oct;38(5):1805-13. doi: 10.1007/s10753-015-0158-5. Inflammation. 2015. PMID: 25820390
-
Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease.BMC Pulm Med. 2020 Dec 7;20(1):318. doi: 10.1186/s12890-020-01362-w. BMC Pulm Med. 2020. PMID: 33287777 Free PMC article.
-
How should we define and classify exacerbations in chronic obstructive pulmonary disease?Expert Rev Respir Med. 2013 Apr;7(2 Suppl):33-41. doi: 10.1586/ers.13.16. Expert Rev Respir Med. 2013. PMID: 23551022 Review.
-
Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review.Cochrane Database Syst Rev. 2021 Jul 26;7(7):CD013384. doi: 10.1002/14651858.CD013384.pub2. Cochrane Database Syst Rev. 2021. PMID: 34309831 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical